Jacobio Pharmaceuticals Group Co., Ltd.

OTCPK:JBPH.F Stock Report

Market Cap: US$614.1m

Jacobio Pharmaceuticals Group Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:JBPH.F Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Sep 25SellUS$735,074CITIC Securities International Asset Management Ltd.Company540,000US$1.36
18 Sep 25BuyUS$10,750,607Yinxiang WangIndividual9,501,350US$1.13
18 Sep 25SellUS$11,882,089Gloryviewpharma LtdCompany10,501,350US$1.13
03 Sep 25BuyUS$269,728Yinxiang WangIndividual209,100US$1.29
02 Sep 25BuyUS$252,960Yinxiang WangIndividual192,300US$1.32
01 Sep 25BuyUS$624Yinxiang WangIndividual600US$1.04
26 Aug 25SellUS$6,056,946Eli Lilly Investment Consulting (Shanghai) Co., Ltd.Company6,000,000US$1.01
18 Aug 25SellUS$7,480,096Eli Lilly Investment Consulting (Shanghai) Co., Ltd.Company8,000,000US$0.94
07 Aug 25SellUS$1,149,540CITIC Securities International Asset Management Ltd.Company1,223,400US$0.94
29 Jul 25BuyUS$2,021Yinxiang WangIndividual2,100US$0.96
25 Jul 25BuyUS$3,842Yinxiang WangIndividual4,200US$0.91
24 Jul 25BuyUS$49,670Yinxiang WangIndividual54,600US$0.91
22 Jul 25BuyUS$199,298Yinxiang WangIndividual221,100US$0.90
21 Jul 25BuyUS$16,324Yinxiang WangIndividual18,900US$0.86
18 Jul 25BuyUS$170,125Yinxiang WangIndividual215,100US$0.79
17 Jul 25BuyUS$56,126Yinxiang WangIndividual77,100US$0.73
16 Jul 25BuyUS$387,835Yinxiang WangIndividual562,200US$0.69
23 May 25SellUS$755,485Hillhouse Investment Management, Ltd.Company1,225,200US$0.62

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of JBPH.F?
Owner TypeNumber of SharesOwnership Percentage
Private Companies8,500,0001.08%
Employee Share Scheme26,806,7653.41%
Institutions81,468,29310.4%
VC/PE Firms86,078,43510.9%
Public Companies87,486,89011.1%
Individual Insiders164,850,52021%
General Public331,481,87742.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 17 shareholders own 57.86% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
15.1%
Yinxiang Wang
118,613,125US$92.6m0%no data
11.1%
Center Laboratories, Inc.
87,486,890US$68.3m0%no data
5.94%
Eli Lilly Investment Consulting (Shanghai) Co., Ltd.
46,734,925US$36.5m0%2.16%
5%
Hillhouse Investment Management, Ltd.
39,343,510US$30.7m0%0.13%
5%
CITIC Securities International Asset Management Ltd.
39,339,900US$30.7m0%59.91%
4.87%
Qiming Weichuang Venture Capital Management (Shanghai) Company Limited
38,327,644US$29.9m0%1.45%
2.96%
Yunyan Hu
23,292,295US$18.2m0%no data
2.92%
Xiaojie Wang
22,945,100US$17.9m0%no data
2.42%
Willgenpharma LImited
19,035,835US$14.9m0%no data
1.08%
Blesspharma Ltd
8,500,000US$6.6m0%no data
0.99%
Gloryviewpharma Ltd
7,770,930US$6.1m0%no data
0.21%
State Street Global Advisors, Inc.
1,636,500US$1.3m0.85%no data
0.2%
First Trust Advisors LP
1,594,965US$1.2m-0.88%no data
0.055%
BlackRock, Inc.
434,100US$338.9k3.88%no data
0.012%
Dimensional Fund Advisors LP
94,000US$73.4k0%no data
0.0052%
Connor, Clark & Lunn Investment Management Ltd.
40,784US$31.8k0%no data
0.00005%
Norges Bank Investment Management
400US$307.00%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/18 23:37
End of Day Share Price 2026/02/18 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jacobio Pharmaceuticals Group Co., Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yu WuCMB International Securities Limited
Ziyi ChenGoldman Sachs
Linhai ZhaoGoldman Sachs